Table 1.
Comparisons of clinical and laboratory characteristics between IPA and non-IPA patients with severe fever with thrombocytopenia syndrome.
| Index | All patients (N = 76) | IPA patients (N = 30) | Non-IPA patients (N = 46) | P value |
|---|---|---|---|---|
| Clinical characteristics, symptoms or signs | ||||
| Age, years | 66.75 ± 9.55 | 66.53 ± 9.05 | 66.89 ± 9.87 | 0.874 |
| Male, N (%) | 46(60.5) | 20(66.6) | 26(56.5) | 0.376 |
| Duration of fever, (days) | 10.55 ± 5.07 | 11.63 ± 5.76 | 9.85 ± 4.5 | 0.135 |
| Cough, N (%) | 48(63.1) | 24(80) | 24(52.2) | 0.014 |
| Hemoptysis, N (%) | 14(18.4) | 10(33.3) | 4(8.7) | 0.007 |
| Dyspnea, N (%) | 19(25) | 12(40) | 7(15.2) | 0.015 |
| CNS symptoms, N (%) | 47(61.8) | 26(86.6) | 21(45.6) | 0.000 |
| Alimentary symptoms, N (%) | 33(43.3) | 13(43.3) | 20(43.4) | 0.924 |
| Laboratory parameters | ||||
| Neutropenia, N (%) | 35(46.1) | 20(66.6) | 15(32.6) | 0.004 |
| Platelet count (x109/L) | 33(20-48) | 21(16-33) | 38(28-53) | 0.000 |
| CD4+ T-cells, (cells/mm3, normal range 410–1590) | 96(56-139) | 58(44-97) | 122(75-200) | 0.000 |
| CD8+ T-cells, (cells/mm3, normal range 190–1140) | 111(61-168) | 67(41-104) | 142(99-218) | 0.000 |
| IL-6,(pg/mL, normal range 0–5.9) | 95(35-197) | 172(132-297) | 44(25-94) | 0.000 |
| TNF-α, (pg/mL, normal range 0–8.1) | 65(35-205) | 137(73-232) | 44(27-80) | 0.000 |
| IL-8, (pg/mL, normal range 0–62) | 89(35-256.8) | 223(126-365.5) | 40(29-98) | 0.000 |
| IL-10, (pg/mL, normal range 0–9.1) | 136(44-413.5) | 260(135.7-509.2) | 86(29-221) | 0.000 |
| BNP, (pg/mL, normal range 0–100) | 174(75-512) | 567(254-1016) | 94(55-189) | 0.000 |
| G test, (pg/mL) | 9.7(5-28.8) | 19(9.8-56) | 5(5-10) | 0.000 |
| GM test, (μg/L) | 0.65 ± 0.45 | 1.06 ± 0.44 | 0.38 ± 0.17 | 0.000 |
| PCT, (mg/L) | 0.7(0.27-1.4) | 0.49(0.18-1.52) | 0.86(0.3-1.3) | 0.127 |
| CRP, (ng/mL) | 15.1(6.5-43.1) | 23.4(9-50.7) | 10.8(3.3-35.3) | 0.031 |
| APTT, (seconds, normal range 28-42) | 71(55-94) | 89(58.9-104.4) | 64.2(50-84) | 0.005 |
| MODS, N (%) | 71(93.4) | 30(100) | 41(89.1) | 0.062 |
| Pancreatic damage, N (%) | 66(86.8) | 29(96.6) | 37(80.4) | 0.041 |
| Renal damage, N (%) | 38(50) | 25(83.3) | 13(28.3) | 0.000 |
| Myocardial damage, N (%) | 69(90.8) | 29(96.6) | 40(86.9) | 0.152 |
| ICU admission, N (%) | 7(9.2) | 7(23.3) | 0 | 0.001 |
| DM, N (%) | 6(7.9) | 3(10) | 3(6.5) | 0.583 |
| Carbapenems application, N (%) | 28(36.8) | 21(70) | 7(15.2) | 0.000 |
| Death, N (%) | 24(31.6) | 16(53.3) | 8(17.4) | 0.001 |
Data are presented as the mean ± standard deviation, median (interquartile range), and proportion.
IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha; IL-8, interleukin-8; IL-10, interleukin-10; MODS, multiple organ dysfunction syndromes; ICU, intensive care unit; DM, diabetes mellitus. BNP, brain natriuretic peptide; G, (1,3)-β-D-glucan; CRP, C-reactive protein; PCT, procalcitonin; GM, galactomannan.